Target intelligence / Profile preview

Natural killer cell-mediated tumor cell lysis (non-MHC-restricted) (NK cell-mediated cytotoxicity)

Target
NK cell-mediated cytotoxicity
Molecular classification
Other
01

Overview

Natural killer (NK) cell-mediated tumor lysis via non-MHC-restricted cytotoxicity" refers to the process by which NK cells recognize and kill tumor cells without the need for antigen presentation through major histocompatibility complex (MHC) molecules. Unlike T-cell mediated killing, which is MHC-restricted and requires specific antigen recognition, NK cells can detect target cells that have down-regulated MHC class I expression—a common feature of many tumors attempting to evade immune detection. This recognition occurs through a balance of activating and inhibitory signals received by various surface receptors on the NK cell. Activating receptors include natural cytotoxicity receptors such as NKp30, NKp44, and NKp46; these can sense stress-induced ligands or changes in heparan sulfate proteoglycans on tumor surfaces[3]. Additionally, antibody-dependent cellular cytotoxicity (ADCC) is a key mechanism where therapeutic antibodies like trastuzumab or cetuximab bind to antigens on tumor cells and engage FcγRIIIa/CD16A receptors on NK cells to trigger targeted killing[2]. This form of immune surveillance plays an important role in cancer immunology but is not itself a single molecular target; rather it describes an effector function involving multiple receptor-ligand interactions. Note: The entry "Tumor cell lysis via non-MHC-restricted cytotoxicity" does not refer to a specific molecule or receptor but rather describes an immunological process primarily mediated by natural killer cells. Therefore, it should not be considered a canonical therapeutic target molecule/receptor; instead, individual components such as "Natural killer cell activating receptor 1" (NKp46), "Fc gamma receptor IIIa", etc., would be appropriate targets for structured data extraction[2][3].

Other names
Non-MHC-restricted cytotoxicityNK cell cytotoxicityNatural killer cell anti-tumor activityNon-classical cytotoxic lymphocyte killing
02

Mechanism of action

Antibody-dependent cellular cytotoxicity (ADCC) via Fc receptor engagement[2]; Direct recognition of stress ligands or down-regulated MHC class I on tumor cells by activating receptors on NK cells[2][3]

03

Biological functions

Immune responseCell death (cytotoxicity)Tumor surveillance
04

Disease associations

Cancer
05

Interacting drugs

Trastuzumab (via ADCC)[2]

2 more in the full profile.

Beyond the preview

Go deeper on Natural killer cell-mediated tumor cell lysis (non-MHC-restricted) (NK cell-mediated cytotoxicity).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer cell-mediated tumor cell lysis (non-MHC-restricted) (NK cell-mediated cytotoxicity).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call